Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA:600267)

Market Cap	12.61B +19.9%
Revenue (ttm)	10.31B +6.4%
Net Income	702.17M +28.4%
EPS	0.60 +26.1%
Shares Out	1.16B
PE Ratio	18.25
Forward PE	23.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,991,700
Average Volume	31,947,781
Open	10.82
Previous Close	10.89
Day's Range	10.64 - 10.92
52-Week Range	8.72 - 13.06
Beta	0.41
RSI	43.96
Earnings Date	Aug 25, 2026

About SHA:600267

Zhejiang Hisun Pharmaceutical Co., Ltd. manufactures and supplies pharmaceutical products in China. It provides active pharmaceutical ingredients and finished dosage form products. The company offers products in the areas of anti-tumor, cardiovascular, anti-infective, liver care, orthopedics, anticancer, anti-parasitic, immunosuppressant, etc.; and weight loss, anti-viral, anti-TB, veterinary pharma, and others. It also provides product consultation and CMO/CRO manufacturing services. The company was founded in 1956 and is headquartered in Taiz...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1956
• Employees: 8,751
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600267

Financial Performance

In 2025, SHA:600267's revenue was 10.55 billion, an increase of 2.03% compared to the previous year's 10.34 billion. Earnings were 540.71 million, a decrease of -10.06%.